natgillin/translations-raw huggingface dataset:
Combivir can make you dizzy and have other side effects that make you less alert. 
Od Combivira možete osjećati omaglicu ili druge nuspojave koje Vam mogu smanjiti pažnju.
The mean ratios of CSF/serum lamivudine and zidovudine concentrations 2-4 hours after oral administration were approximately 0.12 and 0.5 respectively. 
Srednji omjer koncentracija lamivudina u likvoru i serumu 2-4 sata nakon oralne primjene iznosi oko 0,12, a zidovudina 0,5.
These may affect up to 1 in 1000 people: 
Mogu se pojaviti u manje od 1 na 1000 osoba:
Lamivudine and zidovudine have been widely used as components of antiretroviral combination therapy with other antiretroviral agents of the same class (NRTIs) or different classes (PIs, nonnucleoside reverse transcriptase inhibitors). 
Lamivudin i zidovudin se široko primjenjuju kao komponente u kombiniranoj antiretrovirusnoj terapiji s drugim antiretrovirusnim lijekovima iste skupine (nukleozidni inhibitori reverzne transkriptaze) ili drugih skupina (inhibitori proteaze, nenukleozidni inhibitori reverzne transkriptaze).
SPECIAL STORAGE CONDITIONS Do not store above 30°C 
POSEBNE MJERE ČUVANJA Ne čuvati na temperaturi iznad 30oC.
Children weighing between 21 kg and 30 kg: the recommended oral dose of Combivir is one-half tablet taken in the morning and one whole tablet taken in the evening. 
Djeca s tjelesnom težinom između 21 kg i 30 kg: preporučena oralna doza Combivira je pola tablete ujutro i jedna cijela tableta navečer.
Multiple drug antiretroviral therapy containing lamivudine has been shown to be effective in antiretrovirally-naive patients as well as in patients presenting with viruses containing the M184V mutations. 
Kombinirana antiretrovirusna terapija koja sadrži lamivudin pokazala se djelotvornom u bolesnika koji prethodno nisu primali antiretrovirusne lijekove kao i u bolesnika kojima su izolirani virusi s mutacijama M184V.
People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). 
Stare infekcije mogu se ponovno javiti Bolesnici s uznapredovalom HIV infekcijom (SIDA) imaju oslabljen imunološki sustav, te su skloniji razvoju ozbiljnih infekcija (oportunističkih infekcija).
Keep this medicine out of the sight and reach of children. 
Kako čuvati Combivir Lijek čuvajte izvan pogleda i dohvata djece.
The usual starting dose of Combivir is one half tablet (½) taken in the morning and one whole tablet taken in the evening. 
Uobičajena početna doza Combivira je pola (½) tablete ujutro, a jedna cijela tableta navečer.
Methadone/Zidovudine (30 to 90 mg once daily/200 mg every 4 hours) 
metadon/zidovudin (30 do 90 mg jedanput dnevno/ 200 mg svakih 4 sata )
Adults and adolescents weighing at least 30 kg: the recommended dose of Combivir is one tablet twice daily. 
Odrasli i adolescenti tjelesne težine najmanje 30 kg: preporučena doza Combivira je jedna tableta dva puta dnevno.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING BLISTER PACK OUTER CARTON 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU BLISTER PAKIRANJE, KUTIJA
What you need to know before you take Combivir 
Što morate znati prije nego počnete uzimati Combivir Nemojte uzimati Combivir:
The special warnings and precautions relevant to both lamivudine and zidovudine are included in this section. 
U ovom su dijelu navedena posebna upozorenja i mjere opreza koja se odnose na lamivudin i zidovudin.
High doses of trimethoprim/ sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis have not been studied and should be avoided. 
Pneumocystis jirovecii pneumonije (PCP) i toksoplazmoze nisu proučavane, te bi ih trebalo izbjegavati
The usual starting dose of Combivir is one half tablet (½) taken in the morning and one half tablet (½) taken in the evening. 
Uobičajena početna doza Combivira je pola (½) tablete ujutro i pola (½) tablete navečer.
Lamivudine and zidovudine are nucleoside analogues which have activity against HIV. 
Lamivudin i zidovudin su analozi nukleozida s aktivnošću protiv virusa humane imunodeficijencije
Read the information ‘Other possible side effects of combination therapy for HIV' in 
Pozorno pročitajte informacije “Ostale moguće nuspojave u kombiniranoj terapiji za
Skin and subcutaneous tissue disorders Uncommon : Rash and pruritus Rare : Nail and skin pigmentation, urticaria and sweating 
Manje često: osip i svrbež Rijetko: pigmentacija kože i noktiju, urtikarija i znojenje
Methadone dosage adjustment unlikely in majority of patients; occasionally methadone re-titration may be required. 
Potreba za prilagodbom doze za metadon je malo vjerojatna kod većine bolesnika;
Following single dose Combivir administration in healthy volunteers, mean (CV) lamivudine and zidovudine Cmax values were 1.6 µg/ml (32%) and 2.0 µg/ml (40%), respectively and the corresponding values for AUC were 6.1 µg h/ml (20%) and 2.4 µg h/ml (29%) respectively. 
Nakon primjene jedne doze Combivira zdravim dobrovoljcima, srednje (CV) vrijednosti Cmax lamivudina iznosile su 1,6 μg/ml (32%), a zidovudina 2,0 μg/ml (40%), a odgovarajuće vrijednosti AUC
URICOSURIC Probenecid/Lamivudine 
URIKOZURICI probenecid/lamivudin
• chest pain; disease of the heart muscle (cardiomyopathy) 
• bol u prsištu, bolest srčanog mišića (kardiomiopatija) • napadaji (konvulzije)
• stavudine, to treat HIV infection 
• stavudin, za liječenje infekcije HIV-om
2 years 
6.3 Rok valjanosti 2 godine
Uncommon : Myopathy 
Manje često: miopatija
Children weighing from 14 kg to 21 kg: the recommended oral dose of Combivir is one-half tablet taken twice daily. 
Djeca s tjelesnom težinom od 14 kg do 21 kg: preporučena oralna doza Combivira je pola tablete dva puta dnevno.
As well as the side effects listed below for Combivir, other conditions can develop during combination therapy for HIV. 
Osim nuspojava navedenih dolje za Combivir, za vrijeme kombinirane terapije za HIV, mogu se razviti i druge nuspojave.
• a decrease in the number of cells involved in blood clotting (thrombocytopenia) or in all kinds of blood cells (pancytopenia). 
• smanjenje broja stanica važnih za zgrušavanje krvi (trombocitopenija) ili svih vrsta krvnih stanica
A bioequivalence study compared Combivir with lamivudine 150 mg and zidovudine 300 mg tablets taken together. 
U studiji bioekvivalencije uspoređivao se Combivir s lamivudinom 150 mg i zidovudinom 300 mg u obliku tableta, uzimanih zajedno.
In any case, initiation of susceptible NRTI's should always be preferred to maintenance of lamivudine therapy. 
U svakom slučaju, preferira se započinjanje liječenja osjetljivim nukleozidnim inhibitorima reverzne transkriptaze u odnosu na nastavak terapije lamivudinom.
Metabolism and nutrition disorders Rare : Lactic acidosis in the absence of hypoxaemia, anorexia 
Rijetko: laktacidoza u odsutnosti hipoksemije, anoreksija
The 5'-glucuronide of zidovudine is the major metabolite in both plasma and urine, accounting for approximately 50-80% of the administered dose eliminated by renal excretion. 
Glavni metabolit zidovudina u plazmi i urinu je 5'-glukuronid i u tom se obliku bubrezima izlučuje 5080% primijenjene doze lijeka.
Resistance to thymidine analogues (of which zidovudine is one) is well characterised and is conferred by the stepwise accumulation of up to six specific mutations in the HIV reverse transcriptase at codons 41, 67, 70, 210, 215 and 219. 
Rezistencija na analoge timidina (zidovudin je jedan od njih) je dobro karakterizirana stupnjevitom akumulacijom do 6 specifičnih mutacija na HIV reverznoj transkriptazi, na kodonima 41,
Treatment with zidovudine has been associated with loss of subcutaneous fat which is most evident in the face, limbs and buttocks. 
Liječenje zidovudinom bilo je povezano s gubitkom potkožnog masnog tkiva koji je najočitiji na licu,
Combination therapy for HIV can also cause: • increased levels of lactic acid in the blood, which on rare occasions can lead to lactic acidosis 
• povišene razine mliječne kiseline u krvi koje u rijetkim slučajevima mogu dovesti do laktacidoze
• a failure of the bone marrow to produce new red blood cells (pure red cell aplasia). 
• zatajenje stvaranja novih crvenih krvnih stanica iz koštane srži (aplazija crvenih krvnih stanica).
Musculoskeletal and connective tissue disorders Common : Myalgia 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva Često: mijalgija
They are white to off-white, capsuleshaped scored tablets marked with the code GXFC3 on both sides. 
Bijele su do gotove bijele filmom obložene tablete oblika kapsule s razdjelnim urezom i utisnutim natpisom “GXFC3” na obje strane.
Based on these data Combivir may be administered with or without food. 
Na osnovu ovih podataka, ustanovljeno je da se Combivir može uzimati sa i bez hrane.
Laboratorios ViiV Healthcare, S.L. 
VIIVHIV HEALTHCARE, UNIPESSOAL, LDA.
Combivir was shown to be bioequivalent to lamivudine 150 mg and zidovudine 300 mg given as separate tablets, when administered to fasting subjects. 
Pokazano je da je Combivir bioekvivalentan lamivudinu od 150 mg i zidovudinu od 300 mg ako se daju bolesnicima natašte kao odvojene tablete.
• probenecid, to treat gout and similar conditions, and given with some antibiotics to make them more effective 
• amfotericin ili kotrimoksazol, za liječenje gljivičnih i bakterijskih infekcija • probenecid, za liječenje gihta i sličnih stanja, uz terapiju antibioticima radi bolje efikasnosti
The clinically relevant effects of lamivudine and zidovudine in combination are anaemia, neutropenia and leucopenia. 
5.3 Neklinički podaci o sigurnosti primjene Klinički značajni učinci kombinacije lamivudina i zidovudina su anemija, neutropenija i leukopenija.
As dosage adjustment of Combivir is not possible, separate preparations of zidovudine and lamivudine should be used. 
Kako prilagodba doze Combivira nije moguća, potrebno je primijeniti odvojene pripravke zidovudina i lamivudina.
Therapy should be initiated by a physician experienced in the management of HIV infection. 
4.2 Doziranje i način primjene Liječenje treba započeti liječnik s iskustvom u liječenju HIV infekcije.
Very common : Nausea 
Vrlo često: mučnina
Hypromellose (E464), titanium dioxide (E171), macrogol 400, polysorbate 80 
natrijev škroboglikolat silicijev dioksid, koloidni magnezijev stearat Film ovojnica tablete: hipromeloza (E464) titanijev dioksid (E171) makrogol 400 polisorbat 80
MARKETING AUTHORISATION NUMBER(S) EU/1/98/058/001 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/98/058/001
Blood and lymphatic system disorders Common : Anaemia, neutropenia and leucopenia Uncommon: Thrombocyopenia and pancytopenia (with marrow hypoplasia) Rare : Pure red cell aplasia 
Često: anemija, neutropenija i leukopenija Manje često: trombocitopenija i pancitopenija (s hipoplazijom koštane srži) Rijetko: aplazija crvenih krvnih stanica
NAME OF THE MEDICINAL PRODUCT Combivir 150 mg/300 mg film-coated tablets 
NAZIV LIJEKA Combivir 150 mg/300 mg filmom obložene tablete
ANTI-INFECTIVE PRODUCTS Atovaquone/Lamivudine 
ANTIINFEKTIVNI LIJEKOVI atovakon/lamivudin
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS) Ranitidine/Lamivudine 
zidovudin AUC ↑80% (UGT inhibicija) ANTIHISTAMINICI (ANTAGONISTI HISTAMIN H1 RECEPTORA) ranitidin/lamivudin
Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided. 
HIV-1 u slučaju kada se dugotrajna istodobna primjena ne može izbjeći.
ANTIMYCOBACTERIALS Rifampicin/Lamivudine 
ANTIMIKOBAKTERICI rifampicin/lamivudin
Combivir contains lamivudine and zidovudine, therefore any interactions identified for these individually are relevant to Combivir. 
4.5 Interakcije s drugim lijekovima i drugi oblici interakcija Combivir sadrži lamivudin i zidovudin, stoga bilo koja uočena interakcija za individualne komponente je relevantna i za Combivir.
Uncommon : Fever, generalised pain and asthenia Rare :Chills, chest pain and influenza-like syndrome 
Rijetko: zimica, bolovi u prsnom košu i sindrom nalik na gripu
As Combivir contains lamivudine and zidovudine, the type and severity of adverse reactions associated with each of the compounds may be expected. 
Budući da Combivir sadrži i lamivudin i zidovudin, mogu se očekivati nuspojave karakteristične za oba lijeka.
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) ODGOVORAN (NI) ZA PUŠTANJE
In a second study, mice were administered zidovudine at doses up to 40 mg/kg for 24 months, with exposure beginning prenatally on gestation day 10. 
40 mg/kg, počevši prenatalno od 10. dana gestacije.
Other possible side effects of combination therapy for HIV Combination therapy such as Combivir may cause other conditions to develop during HIV treatment. 
Kombinirana terapija kao što je Combivir može uzrokovati druga stanja koja se mogu razviti za vrijeme liječenja HIV-a.
MARKETING AUTHORISATION NUMBER(S) EU/1/98/058/002 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/98/058/002
Early symptoms (symptomatic hyperlactatemia) include benign digestive symptoms (nausea, vomiting and abdominal pain) non-specific malaise, loss of appetite, weight loss, respiratory symptoms (rapid and/or deep breathing) or neurological symptoms (including motor weakness). 
gubitak na tjelesnoj težini, respiratorne simptome (ubrzano i/ili duboko disanje) ili neurološke simptome (uključujući motoričku slabost).
Combivir 150 mg/300 mg film-coated tablets lamivudine/zidovudine 
Combivir 150 mg/300 mg filmom obložene tablete lamivudin/zidovudin
How to store Combivir 
Moguće nuspojave Kako čuvati Combivir
A large amount of data on pregnant women taking lamivudine or zidovudine indicate no malformative toxicity (more than 3000 outcomes from first trimester exposure each, of which over 2000 outcomes involved exposure to both lamivudine and zidovudine). 
Velika količina podataka koja se odnosi na trudne žene koje su uzimale lamivudin ili zidovudin ukazuje da ne postoji malformacijska toksičnost (više od 3000
Treatment with Combivir should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur. 
Ukoliko se jave klinički znakovi, simptomi ili abnormalni laboratorijski nalazi koji ukazuju na pankreatitis, treba smjesta prekinuti liječenje Combivirom.
• fluconazole or flucytosine, to treat fungal infections such as candida 
• flukonazol ili flucitozin, za liječenje gljivičnih infekcija kao što je kandida • pentamidin ili atovakvanon, za liječenje infekcija parazitima kao što je pneumonija izazvana s
Skin and subcutaneous tissue disorders Common: Rash, alopecia Rare: Angioedema 
Često: osip, alopecija Rijetko: angioedem
NAME OF THE MEDICINAL PRODUCT Combivir 150 mg/300 mg tablets Lamivudine/zidovudine 
NAZIV LIJEKA Combivir 150 mg/300 mg tablete lamivudin/zidovudin
OPIOIDS Methadone/Lamivudine 
OPIOIDI metadon/lamivudin
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains lamivudine 150 mg zidovudine 300 mg 
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži: 150 mg lamivudina 300 mg zidovudina
ANTIFUNGALS Fluconazole/Lamivudine 
ANTIMIKOTICI flukonazol/lamivudin
Opportunistic infections: Patients receiving Combivir or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection. 
Oportunističke infekcije: Bolesnici koji uzimaju Combivir ili bilo koju drugu antiretrovirusnu terapiju,
• high doses of co-trimoxazole, an antibiotic 
• visoke doze antibiotika kotrimoksazola • kladribin, koristi se za liječenje leukemije vlasastih stanica
Rare : Oral mucosa pigmentation, taste perversion and dyspepsia. 
Manje često: flatulencija Rijetko: pigmentacija oralne sluznice, promjene osjeta okusa i dispepsija, pankreatitis
During your treatment, your doctor will monitor you for signs of lactic acidosis. 
Vaš liječnik će nadzirati moguću pojavu znakova laktacidoze kod Vas.
General disorders and administration site conditions Common: Fatigue, malaise, fever 
Opći poremećaji i reakcije na mjestu primjene Često: umor, slabost, vrućica
• pyrimethamine, to treat malaria and other parasitic infections 
• pirimetamin, za liječenje malarije i ostalih infekcija parazitima • dapson, za prevenciju pneumonije i liječenje kožnih infekcija
Common : Raised blood levels of liver enzymes and bilirubin Rare : Liver disorders such as severe hepatomegaly with steatosis 
Rijetko: poremećaji jetre poput teške hepatomegalije sa steatozom Poremećaji kože i potkožnog tkiva
Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). 
(hipertonija, konvulzija, abnormalno ponašanje).
Interactions involving binding site displacement are not anticipated with Combivir. 
Za Combivir se ne očekuju interakcije lijekova koje uključuju promjene mjesta vezanja.
Fluconazole/Zidovudine (400 mg once daily/200 mg thrice daily) 
flukonazol/zidovudin (400 mg jedanput dnevno /200 mg triput dnevno)
ANTIRETROVIRAL MEDICINAL PRODUCTS Didanosine/Lamivudine 
LIJEKOVI didanozin/lamivudin
However, as dosage adjustments for zidovudine may be necessary, it is recommended that separate preparations of lamivudine and zidovudine be administered to patients with severe hepatic impairment. 
preporučuje se davanje odvojenih pripravaka lamivudina i zidovudina bolesnicima s teškim oštećenjem jetre.
Valproic acid/Zidovudine (250 mg or 500 mg thrice daily/100 mg thrice daily) 
Na-valproat (valproična kiselina)/zidovudin (250 mg ili 500 mg tri puta dnevno/100 mg tri puta dnevno)
When concomitant administration with cotrimoxazole is warranted, patients should be monitored 
Kada je neizbježna istodobna primjena s kotrimoksazolom,
ANTICONVULSANTS Phenobarbital/Lamivudine 
ANTIEPILEPTICI fenobarbital/lamivudin
Common : Dizziness 
Često: omaglica
Metabolism and nutrition disorders Very Rare: Lactic acidosis 
Poremećaji bubrega i mokraćnog sustava Rijetko: učestalo mokrenje
Uncommon side effects These may affect up to 1 in 100 people: 
Mogu se pojaviti u manje od 1 na 100 osoba:
Hepatobiliary disorders 
ANTIRETROVIRUSNI
Common : Vomiting, abdominal pain and diarrhoea Uncommon : Flatulence 
Često: povraćanje, bol u abdomenu i proljev
DATE OF REVISION OF THE TEXT MM/YYYY 
DATUM REVIZIJE TEKSTA
Cartons containing opaque polyvinyl chloride/foil blister packs. 
6.5 Vrsta i sadržaj spremnika Kartonska kutija sadrži neprozirna polivnilklorid/aluminijska blister pakiranja.
Clarithromycin/Zidovudine (500 mg twice daily/100 mg every 4 hours) 
Odvojena primjena Combivira i klaritromicina kroz najmanje dva sata klaritromicin/zidovudin (500 mg dva puta dnevno/100 mg svakih 4 sata )
Microcrystalline cellulose (E460), sodium starch glycollate, colloidal silicon dioxide, magnesium stearate 
celuloza, mikrokristalična (E460)
Common side effects These may affect up to 1 in 10 people: 
Mogu se pojaviti u manje od 1 na 10 osoba:
Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea Rare: Pancreatitis, rises in serum amylase 
Poremećaji probavnog sustava: Često: mučnina, povraćanje, abdominalna bol ili grčevi, proljev
Reproductive system and breast disorders Rare : Gynaecomastia 
Rijetko: ginekomastija
Section 4 of this leaflet. 
HIV” u dijelu 4 ove upute.
Cardiac disorders Rare :Cardiomyopathy 
Rijetko: kardiomiopatija
Respiratory, thoracic and mediastinal disorders Common: Cough, nasal symptoms 
Često: kašalj, simptomi rinitisa
Valproic acid/Lamivudine 
Na-valproat (valproična kiselina)/lamivudin
An uncommon side effect that may show up in blood test is: 
Vrlo rijetke nuspojave koje se mogu pojaviti u krvnim pretragama su:
Very rare side effects These may affect up to 1 in 10,000 people: 
Mogu se pojaviti u manje od 1 od 10 000 osoba:
clinically. 
LIJEKA
(often referred to as PCP) 
Pneumocystis jirovecii (koja se često naziva PCP)
− If you get any of the side effects talk to your doctor or pharmacist. 
- Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
• numbness 
• omamljenost
MA (EU) number (Invented) name 
Broj EU odobrenja (Novoizumljeno) ime
Oral use bottle (HDPE) 
Filmom obložena tableta Peroralna primjena Boca (HDPE)
The standard dose is one tablet once a day. 
Standardna doza je jedna tableta jedanput dnevno.
Dopamine is important for controlling movement and coordination. 
Dopamin je važan za kontrolu kretanja i koordinacije.
The full EPAR for Rasagiline Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Rasagiline Mylan nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This means that Rasagiline Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Azilect. 
To znači da je Rasagiline Mylan sličan „referentnom lijeku” koji je već odobren u Europskoj uniji (EU) pod nazivom Azilect.
The Committee recommended that Rasagiline Mylan be approved for use in the EU. 
Odbor je preporučio odobrenje lijeka Rasagiline Mylan za korištenje u EU-u.
This is a summary of the European public assessment report (EPAR) for Rasagiline Mylan. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Rasagiline Mylan.
Rasagiline Mylan can be used either alone, or as an add-on to levodopa (another medicine used in Parkinson's disease) in patients who are having fluctuations in the control of their condition. 
Rasagiline Mylan može se koristiti kao monoterapija ili kao dodatak lijeku levodopa (drugom lijeku koji se koristi za liječenje Parkinsonove bolesti) u bolesnika kod kojih su prisutne fluktuacije u kontroli njihova stanja.
By increasing levels of dopamine in the parts of the brain that control movement and coordination, Rasagiline Mylan reduces the symptoms of Parkinson's disease, such as stiffness and slowness of movement. 
Povećanjem razina dopamina u dijelovima mozga koji kontroliraju kretanje i koordinaciju, lijek Rasagiline Mylan smanjuje simptome Parkinsonove bolesti kao što su ukočenost i usporeno kretanje.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rasagiline Mylan has been shown to have comparable quality and to be bioequivalent to Azilect. 
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno kako Rasagiline Mylan posjeduje usporedivu razinu kvalitete te je bioekvivalentan s lijekom Azilect.
Rasagiline Mylan is available as tablets (1 mg). 
Rasagiline Mylan dostupan je u obliku tableta (od 1 mg).
It blocks the enzyme monoamine oxidase type B, which breaks down a substance called dopamine in the brain. 
Djeluje blokiranjem enzima monoamin oksidaze-B koji u mozgu razgrađuje tvar naziva dopamin.
Rasagiline Mylan is a medicine used to treat adults with Parkinson's disease (a progressive brain disorder that causes shaking, slow movement and muscle stiffness). 
Rasagiline Mylan lijek je koji se koristi za liječenje odraslih osoba s Parkinsonovom bolešću (progresivnim moždanim poremećajem koji uzrokuje drhtanje, usporene pokrete i krutost mišića).
The active substance in Rasagiline Mylan, rasagiline, is a ‘monoamine oxidase B inhibitor'. 
Djelatna tvar u lijeku Rasagiline Mylan, razagilin, je "inhibitor monoamin oksidaze-B".
What is Rasagiline Mylan and what is it used for? 
Što je Rasagiline Mylan i za što se koristi?
It is not intended to provide practical advice on how to use Rasagiline Mylan. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Rasagiline Mylan.
What measures are being taken to ensure the safe and effective use of Rasagiline Mylan? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rasagiline Mylan?
A risk management plan has been developed to ensure that Rasagiline Mylan is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Rasagiline Mylan.